A Multimethod Assessment of Juvenile Psychopathy: Comparing the Predictive Utility of the PCL:YV, YPI, and NEO PRI
A Multimethod Assessment of Juvenile Psychopathy: Comparing the Predictive Utility of the PCL:YV, YPI, and NEO PRI
复制标题
DOI：
10.1037/a0017367
复制
发表时间：
2009-12-01
影响因子：
3.6
通讯作者：
Monahan, Kathiyn C.
中科院分区：
文献类型：
--
作者：
Cauffman, Elizabeth;Kimonis, Eva R.;Monahan, Kathiyn C.
目前的研究比较了3种不同的方法来衡量青少年精神病和他们的效用预测短期和长期累犯的样本中的1,170名严重的男性青少年罪犯。评估方法比较了临床访谈方法（精神病检查表：青年版[PCL：YV]; Forth，Kosson，& Hare，2003），一种新的自我报告测量方法（青年精神病特质量表：Andershed，Kerr，Stattin，& Levander，2002），以及一种基于人格的方法（NEO精神病相似指数; Lynam & Widiger，2007）。结果表明，适度的重叠之间的3个措施（rs = 0.26 - 0.36），然而，青年往往被确定为精神病的I措施，而不是由其他。在随后的6个月和12个月期间，措施与重新犯罪的相关性较弱。研究结果表明，虽然这样的分数可能是有用的指标，需要加强监测，在短期内，应采取谨慎的预测青少年长期累犯。此外，PCL：YV缺乏长期预测能力，以及不同测量方法获得的精神病名称不一致，这对使用这些测量方法作为法律的或临床治疗决策的基础提出了严重的问题。
The current study compares 3 distinct approaches for measuring juvenile psychopathy and their utility for predicting short- and long-term recidivism among a sample of 1,170 serious male juvenile offenders. The assessment approaches compared a clinical interview method (the Psychopathy Checklist: Youth Version [PCL:YV]; Forth, Kosson, & Hare, 2003), a new self-report measure (the Youth Psychopathic Traits Inventory: Andershed, Kerr, Stattin, & Levander, 2002), and a personality-based approach (the NEO Psychopathy Resemblance Index; Lynam & Widiger, 2007). Results indicate a modest overlap between the 3 measures (rs = .26-.36); however, youths were often identified as psychopathic by I measure but not by others. Measures were weakly correlated with reoffending during subsequent 6- and 12-month periods. Findings suggest that although such scores may be useful indicators of the need for heightened monitoring in the short term, care should be taken when making predictions about long-term recidivism among adolescents. Moreover, the lack of long-term predictive power for the PCL:YV and the inconsistent psychopathy designations obtained with different measures raise serious questions about the use of such measures as the basis for legal or clinical treatment decisions.